Maxim Group Downgrades NeuroSense Therapeutics Ltd. (NRSN) to Hold Dec 16, 2024 08:13AM
NeuroSense Announces Second Quarter 2022 Financial Results and Provides Business Update Aug 31, 2022 09:00AM
NeuroSense CEO to be Panelist at Maxim Group's Innovations in ALS: Exploring New Treatments In Development on June 28, 2022 Jun 22, 2022 08:30AM
NeuroSense Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT Mar 15, 2022 09:00AM
NeuroSense Therapeutics Announces Closing of Initial Public Offering on Nasdaq Capital Market Dec 13, 2021 04:01PM


Dec 9, 2021 11:27AM IPO for NeuroSense Therapeutics Ltd. (NRSN) Opened at $4.55
Oct 19, 2021 05:44AM NeuroSense Therapeutics (NRSN) Files IPO Registration Statement